Larimar Therapeutics, Inc. (LRMR)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Larimar Therapeutics, Inc. (LRMR) is down 16.0% since the beginning of the year. At $3 per share, LRMR is trading 50.2% below its 52-week high of $6. Investors who bought $1,000 worth of LRMR shares 5 years ago would now be looking at an investment worth $397.

Larimar Therapeutics, Inc. (LRMR) has returned -16.01% so far this year and 32.78% over the past 12 months. Over the last ten years, LRMR has returned -27.82% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Jun 19, 2014, LRMR's average daily return is +0.04%, while the average monthly return is +0.18%. At this rate, an investment would double in approximately 32.1 years.

Historically, 50% of months were positive and 50% were negative. The best month was Feb 2024 with a return of +98.6%, while the worst month was Oct 2015 at -69.9%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 7 months.

On a daily basis, LRMR closed higher 47% of trading days. The best single day was Jan 20, 2016 with a return of +78.7%, while the worst single day was Dec 2, 2015 at -60.6%.

Larimar Therapeutics, Inc. has an annualized alpha of -2.60%, beta of 0.91, and R2 of 0.03 versus S&P 500 Index. Calculated based on daily prices since June 20, 2014.

• This stock participated in 148.54% of S&P 500 Index downside but only -30.60% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.03 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

LRMR ranks 59 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for Larimar Therapeutics, Inc. (LRMR) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Larimar Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Larimar Therapeutics, Inc. was 99.75%, occurring on Aug 5, 2022. The portfolio has not yet recovered.

The current Larimar Therapeutics, Inc. drawdown is 99.48%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Larimar Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Larimar Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.